TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: catheter time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUA Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: HAPU incidence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TB incidence and prevalence
Endpoint domain: Mortality/survival
Primary endpoint: Extravascular lung water (EVLW)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: AaDO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Inter-rater agreement on diagnostic aspects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: muscle mitochondrial abundance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: muscle mitochondrial capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: physical characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of postanesthetic shivering
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical benefit of direct inhibition of Lp-PLA(2) activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maternal employment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Household income above £200
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Otitis media with effusion in children
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Neurological status at discharge (cerebral performance category)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival to hospital admission and discharge
Endpoint domain: Mortality/survival
Primary endpoint: radiographic improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of revisions
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of Life (QALYs)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Subjective treatment efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Poling distance improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EPS decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quality-adjusted time
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: physical distress
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Decreased ketamine-induced functional connectivity in the salience network
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CAPS-CA score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall survival at one year
Endpoint domain: Mortality/survival
Primary endpoint: Free survival disease
Endpoint domain: Mortality/survival
Primary endpoint: Risk of relapse
Endpoint domain: Adverse events/effects
Primary endpoint: Childbirth pain intensity (VAS score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of the active phase of the first stage of labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Migraine disability scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Headache days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acute Grade 2-3 bladder and lower GI tract toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Preparation for decision making
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Completion of discussions between family decision-makers and nursing home care team
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Plasma concentrations of 744 and RPV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy for adenoma differentiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Neck circumference as a cutoff point for metabolic syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Dyspnea with ADL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neonatal Infant Pain Scale (NIPS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum CRP concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total dosage of fentanyl
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FEV(1) after LTD(4) challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Arterial oxygen tension (PaO(2))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Alveolar-arterial oxygen tension difference (AaPO(2))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Meeting PA guidelines
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: AUC(0, infinity) of nateglinide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C(max) of nateglinide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0‐∞ for OPC‐13015
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0‐∞ for OPC‐13213
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: potency‐adjusted total active moiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of large-for-gestational age neonates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: plasma glucose values in target range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: rate of mild hypoglycemia
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients with no hospital admissions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: articular indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: pain score by visual analogue scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: erythrocyte sedimentation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: CYP3A inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of bleeding or thrombosis
Endpoint domain: Adverse events/effects
Primary endpoint: Pulsatility index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: rate of flap loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: donor site complications
Endpoint domain: Adverse events/effects
Primary endpoint: Patient tolerability of the procedure
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: VAS pain scores during corticosteroid injections
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: B-type natriuretic peptide (BNP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency and severity of cerebral vasospasm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Urinary Albumin-to-Creatinine Ratio (UACR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left Ventricular (LV) Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glycaemic response (GR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Insulinaemic response (IR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Good functional outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: stability of aortic arch repair
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase in limb fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change or discontinuation of antidepressant medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: MMP-3 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Coronary plaque volume change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: quality of operative field
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Regional perfusion in brain regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Perineal nerve terminal motor latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: opioid usage
Endpoint domain: Adverse events/effects
Primary endpoint: satisfaction with pain management
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Loss of consciousness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaginal gel spreading coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of neurotoxicity
Endpoint domain: Adverse events/effects
Primary endpoint: proportion of early access
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median reduction in monthly motor seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Success rate of LCBDE+LC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of symptomatic laboratory-confirmed influenza
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Threshold concentrations for a positive NPT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Work of Breathing total (WOBt)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Work of Breathing elastic (WOBel)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Work of Breathing PEEP intrinsic (WOBPeepi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: MIC 90 values against Enterobacteriaceae and Pseudomonas aeruginosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: logarithm of the minimal angle of resolution BSCVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: incidence of microstriae
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of adolescents not performing supervised physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of adolescents spending > 3 h/day in sedentary occupations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreased urinary albumin-to-creatinine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Nocturnal ST-segment depressions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Variation in intestinal microbial composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-assessed confidence in recognising, assessing and managing a sick child
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cumulative rate of CIN2+
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: time to first admission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: costs to Medicare
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: SBP/DBP reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ankle edema reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CPAP use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subjective sexual arousal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: latency to orgasm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: non-fatal myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cmax of Rifampicin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-10 of Rifampicin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Pyrazinamide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-10 of Pyrazinamide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Virologic failure (VF)
Endpoint domain: Mortality/survival
Primary endpoint: Use of extensive counselling
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Eradication of Helicobacter pylori
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: washout rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical response to amitriptyline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total plasma cholesterol level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Death due to coronary heart disease and confirmed nonfatal myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: MMP-9/TP levels in periapical fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cortisol level during mental stressor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Heart rate recovery after mental stressor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sympathovagal balance after mental stressor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: resolution of macular oedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gain of more than 15 letters
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Quality of Life (QOL) ED scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Perioperative verbal pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hepatic SvO2 (HSvO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Corneal swelling response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severity of disease states
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cervical ripening within 12 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum sex hormone‐binding globulin (SHBG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: plasma nitric oxide (NO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: modified Ferriman Gallwey (mF‐G) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: microleakage score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptable intubating conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vocal cord injuries
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of moderate/severe early OHSS
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of ultrasound evidence of ascites
Endpoint domain: Adverse events/effects
Primary endpoint: Proportions of patients with plasma HIV RNA levels ≤400 copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD4+ T-cell decrease from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Detection of NNRTI-associated resistance mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-h postprandial plasma glucose (ppPG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of patients achieving postprandial blood glucose targets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Nocturnal hypoglycemia rate
Endpoint domain: Adverse events/effects
Primary endpoint: Peripapillary Retinal Nerve Fiber Layer Thickness (PRNFLT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-year tumor-free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: AUC values for daidzein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C(max) values for daidzein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hamilton Rating Scale score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma homocysteine decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of women showing good response (>50% reduction in score)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Three-year Disease-Free Survival (DFS)
Endpoint domain: Mortality/survival
Primary endpoint: Three-year Overall Survival (OS)
Endpoint domain: Mortality/survival
Primary endpoint: Cumulative incidence of Peripheral Sensory Neuropathy (PSN)
Endpoint domain: Adverse events/effects
Primary endpoint: Adjusted mortality
Endpoint domain: Mortality/survival
Primary endpoint: incidence rates of urinary incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Plasminogen activator inhibitor‐1 (PAI‐I)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Factor VII-tissue factor complex (VIIa‐rTF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Tissue-type plasminogen activator antigen (t‐PA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: CM TG-adjusted lycopene response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 13-year cumulative mortality from colorectal cancer
Endpoint domain: Mortality/survival
Primary endpoint: Estimated Survival Time (EST)
Endpoint domain: Mortality/survival
Primary endpoint: Overall Survival Time (OST)
Endpoint domain: Mortality/survival
Primary endpoint: Monocular and binocular contrast sensitivity without glare
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uncorrected intermediate visual acuity (VA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance-corrected intermediate visual acuity (VA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of flare-free treatment days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time to first relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasal Cross-Sectional Area (NCV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasal Mucosal Compliance (NMCA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cultivable bacteria growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: patient perceived comfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: GBP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of spasm
Endpoint domain: Adverse events/effects
Primary endpoint: Access site crossover rate
Endpoint domain: Adverse events/effects
Primary endpoint: Patient discomfort visual analogue scale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: self-reported reductions in peer aggression
Endpoint domain: Adverse events/effects
Primary endpoint: self-reported reductions in alcohol consequences
Endpoint domain: Adverse events/effects
Primary endpoint: toe temperature change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical and role functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Scores on the nutrition and health survey
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preferences for fruits and vegetables
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HBV DNA clearance rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SF-36 mental component summary scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: EQ-5D utility index scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Trough FEV1 at 24 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean TDI focal scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean SGRQ total scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Systolic function differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes